EGFR and non-small cell lung carcinoma: Due to the obvious drug resistance and severe side effects of cisplatin and docetaxel, the seeking of novel chemotherapeutics and chemical scaffolds of chemotherapeutics for NSCLC patients with wild type EGFR is necessary7, 8.